RUBICON RESEARCH (RUBICON) Share Price Falls 2.29% Today

RUBICON Share Price fell to Rs 1,818.50 on 09 September 2026, down 2.29% or Rs 42.65 from the previous close of Rs 1,861.15. The Large Cap healthcare stock now carries a market capitalisation of Rs 28,948.22 crore, putting RUBICON RESEARCH back in focus across Stock Market Today searches and pharma stock updates.

Today’s move is notable because the stock opened at Rs 1,872.30, which was also the day’s high, and then moved lower to an intraday low of Rs 1,814. The supplied data confirms the RUBICON Share Price fall, but it does not establish a company-specific catalyst behind the decline. That makes the current discussion more about verified price action, valuation and positioning than about an unconfirmed headline.

For investors tracking RUBICON Share Price Today, the key questions are straightforward: what exactly happened in the session, how strong the underlying momentum still looks from the available indicators, how expensive or justified the valuation appears, and how the company compares with peers in Pharmaceuticals & Drugs. In this Univest analysis, the focus stays on the numbers that are actually available and what investors should monitor next.

RUBICON RESEARCH (RUBICON) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,818.5
Previous Close	Rs 1,861.15
Today's Move	-Rs 42.65 (-2.29%)
Open	Rs 1,872.3
High	Rs 1,872.3
Low	Rs 1,814
Turnover	Rs 1.95 crore
Market Capitalisation	Rs 28,948.22 crore
Market Cap Category	Large Cap

RUBICON Share Price Today reflects a clear intraday decline from the opening level, with the stock unable to hold its early price zone. It opened at Rs 1,872.30, touched a high of Rs 1,872.30, then slipped to a low of Rs 1,814 before trading at Rs 1,818.50, down Rs 42.65 from the previous close of Rs 1,861.15.

That sequence matters. The fact that the session high matched the opening price suggests the stock came under pressure soon after trade began rather than building follow-through above the prior close. The difference between the day high of Rs 1,872.30 and the last traded level of Rs 1,818.50 shows that sellers retained control for most of the session’s visible price action. At the same time, the current price remains slightly above the intraday low of Rs 1,814, so the stock is off its weakest level of the day.

Turnover stood at Rs 1.95 crore, which confirms active market attention around the counter even without establishing a direct reason for the decline. For a Large Cap name in Healthcare, this RUBICON Share Price Update is drawing attention because the fall is happening in a stock that already trades at elevated valuation multiples. That naturally shifts the discussion from the day’s price move toward technical position and broader stock analysis.

RUBICON RESEARCH (RUBICON) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 28,948.22 crore
P/E Ratio	106.89x
P/B Ratio	22.95x
ROE	27.84%
ROCE	29.22%
EPS	Rs 17.41
Book Value Per Share	Rs 81.09
Dividend Yield	0.08%

RUBICON Fundamental Analysis points to a company with strong reported profitability ratios but a rich valuation. The stock’s market capitalisation is Rs 28,948.22 crore, while the P/E ratio stands at 106.89 and the P/B ratio at 22.95. On the profitability side, ROE is 27.84% and ROCE is 29.22%, both strong on an absolute basis and important in explaining why the market may be assigning a premium multiple.

EPS comes in at 17.41, which indicates the earnings attributable to each share at the current reporting base. Book value per share is Rs 81.09, showing the accounting net worth backing each share. Dividend yield is 0.08, which signals that the stock’s historical payout relative to the current price is modest and that the investment case, based on supplied data, is more valuation and profitability driven than income led.

For RUBICON Share Price Today, the central tension is clear: strong return ratios coexist with an expensive earnings and book-value multiple. A high P/E ratio does not by itself invalidate the business, but it does raise the bar for sustained financial quality in future RUBICON Earnings and RUBICON Financial Results. From a Univest perspective, that is why today’s share price fall is attracting added attention rather than being treated as a routine fluctuation.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	106.89x
Benchmark Median P/E	32.19x
Benchmark Average P/E	49.13x
Benchmark P/E Range	3.39x to 668.68x
Company P/B Ratio	22.95x
Benchmark Median P/B	3.05x
Benchmark Average P/B	4.44x
Company ROE	27.84%
Benchmark Median ROE	11.82%
Benchmark Average ROE	11.12%
Company ROCE	29.22%
Benchmark Median ROCE	13.71%
Benchmark Average ROCE	13.62%
Company Market Capitalisation	Rs 28,948.22 crore
Benchmark Median Market Cap	Rs 715.6 crore
Benchmark Average Market Cap	Rs 14,150.82 crore

RUBICON operates in Healthcare, specifically the Pharmaceuticals & Drugs industry, so the best way to read today’s decline is against that benchmark. The supplied same-industry dataset covers 201 companies and shows RUBICON trading at materially higher valuation multiples than broad sector medians and averages, even though its profitability ratios are also stronger.

Within this same industry benchmark, RUBICON’s P/E of 106.89 stands far above the median of 32.19 and the average of 49.13. The overall P/E range in the sample runs from 3.39 to 668.68 across 169 companies with valid P/E data, so the stock is clearly positioned toward the higher end of sector valuation. The pattern is similar on price to book: RUBICON’s P/B of 22.95 is well above the median of 3.05 and the average of 4.44, though still below the benchmark maximum of 27 among 200 companies.

Profitability tells a different story. RUBICON’s ROE of 27.84% is comfortably ahead of the sector median of 11.82% and average of 11.12. ROCE of 29.22% also exceeds the median of 13.71% and average of 13.62. Market-cap context is important too: at Rs 28,948.22 crore, the company is far above the industry median market capitalisation of Rs 715.60 crore and above the average of Rs 14,150.82 crore, although still well below the sector leader at Rs 4,55,825.66 crore. Univest therefore sees a stock priced at a premium not only to the typical pharma company, but also supported by above-benchmark return metrics.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,55,825.66	37.31	5.22	14.85	19.11
Divi's Laboratories	DIVISLAB	2,47,018.51	86.86	14.38	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,86,874.73	86.55	21.03	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,15,211.69	25.42	4.25	19.69	21.39
Cipla	CIPLA	1,12,773	33.17	3.18	11.83	16

Peer data shows why RUBICON Share Price News is drawing interest after today’s decline. Against large listed pharmaceutical names, RUBICON’s valuation stands out as richer than most. Its P/E of 106.89 is above Sun Pharmaceutical Industries at 37.31, Zydus Lifesciences at 25.42 and Cipla at 33.17, and even above Divi’s Laboratories at 86.86 and Torrent Pharmaceuticals at 86.55.

The P/B ratio tells a similar story. RUBICON trades at 22.95 times book value, above Sun Pharma’s 5.22, Divi’s 14.38, Torrent’s 21.03, Zydus’ 4.25 and Cipla’s 3.18. Yet the return ratios remain competitive. Its ROE of 27.84% is higher than Sun Pharma’s 14.85%, Divi’s 16.19%, Torrent’s 26.76%, Zydus’ 19.69% and Cipla’s 11.83%. ROCE of 29.22% is also above Sun Pharma’s 19.11%, Divi’s 21.51%, Torrent’s 19.27%, Zydus’ 21.39% and Cipla’s 16.00%.

Market-cap scale is where RUBICON is smaller than these peers. At Rs 28,948.22 crore, it trails Sun Pharma at Rs 4,55,825.66 crore, Divi’s at Rs 2,47,018.51 crore, Torrent at Rs 1,86,874.73 crore, Zydus at Rs 1,15,211.69 crore and Cipla at Rs 1,12,773 crore. The peer picture is therefore balanced: superior return ratios versus several peers, but a much sharper valuation premium despite a smaller market-cap footprint.

Why Investors Are Watching RUBICON

• Price action: The stock fell 2.29% to Rs 1,818.50 after opening at the day’s high of Rs 1,872.30.
• Momentum context: RSI at 57.51 suggests momentum is broadly neutral to moderately firm despite today’s decline.
• Valuation: P/E of 106.89 and P/B of 22.95 remain far above same-industry medians.
• Profitability: ROE of 27.84% and ROCE of 29.22% are stronger than sector averages and several peers.
• Sector position: The company sits in Pharmaceuticals & Drugs, with market capitalisation above the industry average of Rs 14,150.82 crore.

About RUBICON

RUBICON RESEARCH is part of the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. Based on the supplied data, the company is best understood as a listed pharma business with a market capitalisation of Rs 28,948.22 crore, placing it meaningfully above the median size of companies in its industry universe. Its current market positioning combines premium valuation multiples with above-benchmark ROE and ROCE, which helps explain why RUBICON Share News and RUBICON Company News remain closely tracked during sharp day-to-day price moves.

Track RUBICON Share Price on Univest

UseRUBICON RESEARCH (RUBICON) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

On Univest, investors can track RUBICON Share Price Live, daily price action, market capitalisation, valuation ratios, sector comparison, peer benchmarks and key return metrics in one place. Univest also helps users monitor indicators such as RSI, moving averages, 52-week levels when available, and broader market insights so that RUBICON Stock News can be read alongside context rather than in isolation.

Frequently Asked Questions

Why is RUBICON Share Price falling today?

Ans. RUBICON Share Price fell 2.29% to Rs 1,818.50 from the previous close of Rs 1,861.15. The supplied data confirms the decline, but it does not establish any company-specific catalyst behind today’s move.

What is RUBICON Share Price Today?

Ans. RUBICON Share Price Today is Rs 1,818.50. The stock is down Rs 42.65, or 2.29%, in the current session after opening at Rs 1,872.30 and moving within a day range of Rs 1,814 to Rs 1,872.30.

What does today’s price action show for RUBICON?

Ans. Today’s price action shows RUBICON opened at Rs 1,872.30, which was also the session high, then declined to Rs 1,814 before trading at Rs 1,818.50. That pattern indicates weakness after the opening level rather than follow-through buying.

Is RUBICON a large-cap stock?

Ans. Yes, RUBICON is classified as a Large Cap stock in the supplied data. Its market capitalisation stands at Rs 28,948.22 crore, which is also above the Pharmaceuticals & Drugs industry average market capitalisation of Rs 14,150.82 crore.

Is RUBICON expensive compared with its sector?

Ans. RUBICON appears expensive versus its same-industry benchmark on valuation multiples. Its P/E is 106.89 against a sector median of 32.19 and average of 49.13, while its P/B of 22.95 is above the median 3.05 and average 4.44.

How strong are RUBICON’s profitability ratios?

Ans. RUBICON shows strong reported profitability ratios. ROE stands at 27.84% and ROCE at 29.22%, both comfortably above the Pharmaceuticals & Drugs benchmark medians of 11.82% and 13.71%, respectively, according to the supplied sector snapshot.

What do EPS, book value and dividend yield indicate for RUBICON?

Ans. RUBICON has EPS of 17.41, book value per share of Rs 81.09 and dividend yield of 0.08. Together, these figures show earnings support, accounting net worth per share and a relatively modest historical payout at current prices.

How does RUBICON compare with major pharma peers?

Ans. RUBICON trades at a higher P/E than Sun Pharma, Divi’s, Torrent, Zydus and Cipla, but its ROE of 27.84% and ROCE of 29.22% are stronger than those peers in the supplied comparison set.

What should investors monitor next in RUBICON Stock News?

Ans. Investors should monitor whether RUBICON Share Price holds near today’s low of Rs 1,814, how valuation multiples compare with peers, and whether future RUBICON Financial Results continue supporting its premium P/E, P/B, ROE and ROCE profile.